|
Editor’s Note: As we prepare to publish, the Nasdaq Composite has fallen 4%. Please be on the lookout for Jeff’s analysis of the recent market action in an upcoming edition. |
Dear Reader,
Eight mice.
That is the extent of the clinical trial conducted by Pfizer for its new bivalent (BA.4/BA.5) COVID-19 booster shot. Pfizer, and the Centers for Disease Control and Prevention (CDC), declared that the trial was a success on the basis of increased antibody production by the mice. Not humans, mice. Eight of them.
This led Rochelle Walensky, Director of the CDC, to endorse the new booster on September 1. She gave her endorsement hours after the CDC Advisory Committee on Immunization Practices voted, 13-1, to support the use of the new booster shots from Pfizer for ages 12 years and older, and Moderna for those 18 years and older.
Walensky stated that her endorsement “followed a comprehensive scientific evaluation and robust scientific discussion.”
This robust scientific discussion was based on the antibody response of eight mice. No safety study was part of the clinical trial.
And based on that information, the current U.S. government ordered 171 million doses of the new boosters from Pfizer and Moderna. Worse, the CDC is recommending that everyone take these shots… based on the results from eight mice.
It’s hard to imagine something so absurd and completely dangerous. We’ve already learned that the spike protein, that the COVID “vaccines” coaxes our bodies into making, is toxic. And contrary to what the CDC originally told us, it doesn’t leave our bodies within a matter of days. Recent studies have already shown that it can persist for more than a year.
And as we’ve learned, these experimental drugs are not without side effects.
The latest data from the CDC documents more than 1.4 million severe adverse events (SAE) resulting from the COVID-19 “vaccines.” Out of that number, 30,796 of those were deaths, 16,501 heart attacks, 52,106 reports of myocarditis/pericarditis, 57,598 have become permanently disabled, and 5,009 miscarriages, among a long list of other SAEs.
And yet the CDC and the pharmaceutical companies felt that injecting these experimental drugs into eight mice, with no human studies, was sufficient and safe for rolling out the boosters to the entire nation. If anyone is skeptical, I wouldn’t blame them one bit.
We’re told that the side effects are “rare” and there is no cause for concern. I recognize that rare might be considered subjective… What’s rare to one may not be rare to another. But 1.4 million and counting doesn’t seem all that rare to me.
And the more we learn about the instances of myocarditis caused by the COVID-19 mRNA “vaccines,” the less rare – and more common – it becomes. Robust research has been performed already, and I think that the numbers below will be shocking. The instances of myocarditis across two key age groups are:
Ages 12–17: 1 out of every 2,650 present myocarditis
Ages 18–24: 1 out of every 1,861 present myocarditis
The above numbers aren’t a typo… It’s not one out of a million. The instances of myocarditis aren’t rare from my perspective. With the numbers above, they are common.
These instances primarily impact healthy young boys/men. This is the same population that is at far less risk of severe illness from COVID-19 compared to a common influenza. And yet, myocarditis can result in heart attacks, and thus death, when the heart is stressed through exercise or stressful situations.
The risk of myocarditis from the COVID “vaccines” has been acknowledged recently by a CDC official, Sara Oliver, to which she stated that the new boosters will carry a similar risk profile. That, in itself, is frightening given the numbers above… But the reality may be worse.
The new boosters cause the body to make new spike proteins that represent the new variants of COVID-19. Again, there has been no safety testing, and no human clinical trials, to determine the effectiveness or risks of these new boosters.
Two recent quotes from top U.S. Food and Drug Administration (FDA) officials are equally concerning:
“It’s like a horror movie I’m being forced to watch and I can’t close my eyes. People are getting bad advice and we can’t say anything.”
“I can’t tell you how many people at the FDA have told me, ‘I don’t like any of this, but I just need to make it to my retirement.’”
Comments like these are deeply disturbing. And the lack of rigor in testing and safety further destroys trust.
It’s time to hit the “pause” button. The risks are far too high for an entire population. Biopharma needs to return to the drawing board and develop something that actually provides sterilizing immunity, and does not cause severe adverse events (including death).
It would be a tragic comedy if it weren’t all true. But it is. And the most absurd result from the eight-mouse clinical trial is that all of the injected rodents contracted COVID-19. That’s right, the new and improved shots, just like the old ones, do not stop infection, replication, or transmission of COVID-19.
Well done. I guess in the eyes of the CDC and the U.S. government, that’s worthy of a nationwide rollout… not in my book, not for my body, nor for that of my kids.
NASA just released data from its Mars Oxygen In-Situ Resource Utilization Experiment (MOXIE). And it’s quite extraordinary…
We first talked about the MOXIE experiment in April of last year. This is one of the experiments that NASA’s Perseverance Rover is conducting on the surface of the Red Planet.
If we remember, NASA equipped Perseverance with an advanced instrument designed to convert carbon dioxide, from the Martian atmosphere, into oxygen. It extracts the two oxygen atoms in each unit of carbon dioxide and then outputs them in the form of breathable oxygen.
Here’s a visual of the rover with the MOXIE instrument attached on the top:
Perseverance Rover
Source: Space.com
Here we can see the MOXIE instrument attached to Perseverance. And NASA now has over 12 months’ worth of data from the instrument at work.
The data shows that MOXIE can produce 15 minutes’ worth of oxygen per hour over the course of seven-hour production runs. That equates to just over 100 minutes of breathable oxygen every seven hours.
That may not seem like much, but this is a game changer. Now we know that it is possible to produce oxygen from carbon dioxide in the Martian atmosphere. The MOXIE experiment was a fantastic success.
All that’s left to do is scale up the production. We could do that using a series of pumps and compressors… That would allow the process to run all day long at a much greater scale. The result would be far more oxygen production – enough to power a human presence on Mars.
I envision that we would build such a system on Earth in the form of an oxygen-production factory module. We could then launch that module into space and deliver it directly to Mars for commissioning. It’s like shipping a pre-built factory to its end destination for assembly and commissioning… The only difference is that the origin is Earth, and the final destination is Mars.
This is the only way to maintain a sustainable presence on Mars. And we already have the launch vehicles – The SpaceX Super Heavy rocket with its Starship is a perfect vehicle to make this delivery a reality.
So the MOXIE experiment is yet another step toward enabling a human presence on Mars. And that means the human race is getting closer to becoming a multi-planetary species.
One of Japan’s largest convenience store chains just announced it is going to use robotics to solve an ongoing labor shortage. This is the beginning of a trend that will spread across the world.
As regular readers know, I lived and worked in Japan for almost two decades as a corporate high-tech executive… And convenience stores play an integral role in Japanese life. I have to say, since returning to the U.S., I definitely miss the convenience.
Consumers in Tokyo can find convenience stores on nearly every street corner. And many of them are open 24/7. They are ridiculously handy. People can pop in for snacks and drinks at any time.
Of course, it’s not easy to staff a store that’s always open, especially in Japan… a rapidly aging society with very restrictive immigration policies that impact the labor market.
And that’s where robotics comes in.
Japan’s FamilyMart stores are deploying an artificial intelligence (AI)-powered robot called TX SCARA to keep the shelves constantly stocked. Here it is in action:
TX SCARA
Source: AP News
Here we can see TX SCARA positioned in a small section of the store that’s behind the consumer-facing drink shelves and in front of the larger drink inventory. When a consumer takes a particular drink from the shelf, TX SCARA grabs a replacement from the inventory and slides it into the proper place on the consumer-facing shelf.
This is such an obvious application of AI and robotics. And it makes perfect sense for convenience stores around the world.
TX SCARA is getting its start in Japan since many stores are open 24/7. But it won’t be long before convenience stores globally adopt this kind of technology as well… especially in places that are still experiencing labor shortages, such as the U.S.
And in most markets where the stores aren’t open 24 hours, this type of AI-powered robot can roam the aisles in a store, restocking shelves, when the store is closed. By morning, the store will be ready for business.
This employment of AI-powered technology is perfect for addressing the labor shortages that are so common today, and also reducing operational expenses for a store, hopefully resulting in lower prices for consumers.
The Great Recalibration is actively underway, and it’s picking up speed even in places that we might not expect.
For the sake of new readers, the Great Recalibration refers to the reshoring of manufacturing for high technology in America and Europe. This is a massive trend right now. It’s all about creating more resilient supply chains and bringing manufacturing closer to its end markets.
Micron Technology has announced that will soon be building in Idaho. The company has said will invest $15 billion to build a brand-new memory chip plant in Boise.
Subscribers of The Near Future Report know Micron Technology (MU) well. We invested in the company back in 2020, and we’re still showing a more than 15% return on the position, despite the market turbulence that we saw in the first half of the year.
Currently, Micron is one of the biggest producers of memory chips on the planet. These chips are used in virtually every electronic device today.
And with this move, Micron is building the first semiconductor fab for memory on U.S. soil in the last 20 years. This is a great development.
Almost all memory production moved offshore to Asia several decades ago. By bringing production back to the U.S., Micron is helping create a robust supply chain that’s not nearly as exposed to supply shocks.
And this is just the beginning… This $15 billion investment is part of Micron’s $40 billion commitment to expand U.S.-based production this decade.
Regards,
Jeff Brown
Editor, The Bleeding Edge
The Bleeding Edge is the only free newsletter that delivers daily insights and information from the high-tech world as well as topics and trends relevant to investments.
The Bleeding Edge is the only free newsletter that delivers daily insights and information from the high-tech world as well as topics and trends relevant to investments.
